The AMR Brief

November Edition · November 2, 2026

Welcome to the first edition of The AMR Brief. We examine four recent developments that matter to businesses building, funding, and adopting technology in healthcare and life sciences, with a practical view of the legal and commercial decisions behind the headlines.

A human hand reaches from the left toward a sleek robotic hand extending from the right, their fingertips nearly touching. The robot’s pale metallic fingers have glowing cyan joints and iridescent details. Set against a soft, pale gray-blue background, the image evokes connection between people and technology.

Canada puts healthcare AI contracts under the microscope

CANADA | PRIVACY AND HEALTHCARE AI | OCTOBER 29, 2026

On October 29th, Canada’s federal, provincial, and territorial privacy regulators announced a joint resolution on AI in healthcare and health research. Adopted on September 15th, the resolution calls for stronger governance throughout an AI system’s life cycle, including lawfully sourced training data, ongoing risk assessments, and human oversight.

The recommendations expressly reach vendor contracts. Healthcare providers are urged to exercise due diligence when procuring AI systems and contracting with vendors and subcontractors. Contracts should address auditing, record keeping, privacy and security training, and restrictions on unauthorized commercialization or disclosure of information. The resolution does not itself create new legislation, but it provides a clear statement of regulators’ expectations for responsible AI governance and accountability, while emphasizing the need to comply with existing applicable privacy laws. It also calls on governments to consider legislative and regulatory measures to strengthen these protections.

The AMR perspective. For clinics, digital health companies, and AI vendors, procurement and licensing terms deserve attention before deployment. Permitted data uses, subcontractor access, and ongoing monitoring should be clear, with responsibility allocated for responding when a system produces harmful or unreliable outputs.

Washington proposes new limits on biotech investment

UNITED STATES | CROSS-BORDER INVESTMENT | OCTOBER 22, 2026

Biotech financing could face a new national security hurdle. On October 22nd, the U.S. Treasury proposed expanding its Outbound Investment Security Program to cover specified biotechnology activities. The proposal targets certain U.S.-person investments involving covered foreign persons with connections to countries of concern, including China.

The proposed scope reaches pharmaceutical technologies such as cell and gene therapies and monoclonal antibodies, as well as certain sequencing and bioinformatics technologies. Certain equity investments and joint ventures could be prohibited where the relevant coverage tests are met. Published in the Federal Register on October 26th, the measure remains a proposal, it is not yet in force. Comments are due December 7th, 2026, with final implementing regulations and their effective date to follow.

The AMR perspective. Canadian biotech businesses with U.S. investors and relevant foreign operations or partners should assess the implications early. Ownership and control, the precise technology involved, and transaction structure could affect investor participation and closing conditions. These questions belong in financing and partnership planning before the deal timetable is fixed.

Europe gives health AI developers a clearer compliance route

EUROPEAN UNION | AI AND MEDTECH | OCTOBER 19, 2026

For businesses developing AI for the European market, a key part of compliance planning has become more concrete. On October 19th, the European Commission announced the first harmonized standard supporting the EU AI Act. EN 18286:2026 addresses quality management systems for providers of high-risk AI.

Applying the standard provides a presumption of conformity with the Article 17 requirements it covers. For medtech companies, it can be integrated with existing quality systems, including ISO 13485. Adoption is voluntary, and the standard does not establish compliance with every AI Act obligation or replace medical device requirements.

The AMR perspective. Developers planning EU entry should map the standard against their existing quality systems and budget for the gaps. For investors and acquirers, this creates a more specific diligence question: what evidence supports the company’s compliance plan, and what will implementation cost? Those answers can inform commercialization milestones and transaction terms.

Pathos secures USD 237 million for AI drug development

UNITED STATES | BIOTECH FINANCING AND DATA LICENSING | OCTOBER 23, 2026

New financing puts a substantial figure behind the commercial potential of AI in drug development. On October 23rd, Pathos AI announced the closing of a USD 237 million Series E financing led by Bristol Myers Squibb, at a post-money valuation of approximately USD 3 billion. It also announced collaborations with Bristol Myers Squibb and Tempus AI focused on Alzheimer’s disease and other neurological conditions.

The data arrangements are particularly instructive. Tempus’s SEC filing describes a five-year agreement to use commercially reasonable efforts to deliver 500,000 de-identified neurology patient records to Pathos, with fees of up to USD 55 million. Accordingly, the data licensing component of the payment depends on the number of records delivered.

The AMR perspective. This deal illustrates the commercial value of combining AI capabilities with access to usable clinical data. For companies negotiating similar collaborations, data-use permissions, exclusivity, sublicensing, and ownership of resulting intellectual property warrant close attention. Those terms help determine what each party can actually develop, share, and commercialize.